Loading clinical trials...

COMPLETEDPHASE2

Study of the Angiogenesis by PET/CT in Patients With Lymphoma

Study of the Angiogenesis Measured by PET/CT With 18F-RGD-K5 in Patients With Lymphoma : a Preliminary Study

NCT02490891•Centre Henri Becquerel

Summary

The aim of the study is to measure tumoral angiogenesis modifications by RGD-K5 PET/CT before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral mass

Detailed Description

After inclusion PET scans with FDG tracer and with a specific tracer of angiogenesis will be performed on patient with lymphoma. After two cycles of chemotherapy PET scans with the same tracers will be performed. Overall survival and disease free survival will be monitored during 18 months.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or Female
•Age ≥ 18 years old
•OMS ≤ 1
•Histological diagnosis of diffuse large B-cell lymphoma what ever the subtype
•Presence of measurable tumor with at least a node mass superior to 3 centimeters
•Stage I to IV
•Inform consent signed

Exclusion Criteria

•Primary cerebral lymphoma
•Absence of fixing on FDG-PET exam
•Pregnant , child bearing, breast feeding or without effective contraception method woman
•Hypersensitivity to RGD-K5
•Hypersensitivity to FDG
•Poorly controlled diabètes (glycemia ≥ 10 millimoles/liter)
•Neoplastic disease (less than 2 years or in progression)

Locations (1)

Centre Henri Becquerel

Rouen, France

Key Dates

Start Date

November 13, 2015

Primary Completion Date

December 14, 2018

Completion Date

October 16, 2020

Last Updated

January 2, 2026

Enrollment

ACTUAL participants

Conditions

Lymphoma

Interventions

RGD K5 PET scan

DEVICE

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

DLBCLDiffuse Large B-Cell Lymphoma

View study

RECRUITINGPHASE1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of the Angiogenesis by PET/CT in Patients With Lymphoma

Inclusion Criteria

Exclusion Criteria

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

U69-CART-Cells For R/R T-ALL